Clinical trials: IDH Mutation
Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or…
- Conditions
- Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2, Oligodendroglioma, Oligodendroglioma IDH-mutant and 1p/19q-codeleted
- Trial name
- NCT07712757
- Testing
- Safusidenib
- Volunteers
- 140 people
- Sponsor
- Nuvation Bio Inc.
Astrocytoma, IDH-Mutant, Grade 3
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation.
- Trial name
- NCT07215910
- Testing
- Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning
- Where
- 152 sites in United States
- Volunteers
- 408 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer.
- Trial name
- NCT01385150
- Testing
- mutation analysis, protein analysis, laboratory biomarker analysis
- Volunteers
- 220 people
- Sponsor
- Eastern Cooperative Oncology Group
Glioma, Brain Tumor
Non-invasive Glioma Characterization Through Molecular Imaging
MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.
- Conditions
- Glioma, Brain Tumor, Primary Brain Tumor, Malignant Glioma
- Trial name
- NCT03684109
- Testing
- 3T MRI Scanner
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
High Grade Glioma, Brain Cancer
Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Immune checkpoint blockade therapies targeting the immunomodulatory effect of cytotoxic T-lymphocyte antigen (CTLA-4) and programmed cell death-1/ Programmed death-ligand 1 (PD-1/PD-L1) have recently demonstrated survival benefit…
- Trial name
- REVOLUMAB (NCT03925246)
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioma, Cholangiocarcinoma
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
This is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment of isocitrate dehydrogenase or (IDH) mutated solid tumors.
- Conditions
- Glioma, Cholangiocarcinoma, Solid Tumor, IDH Mutation
- Trial name
- SOLID (NCT03991832)
- Testing
- Olaparib, Durvalumab
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- University Health Network, Toronto
Brain Tumor, Cancer
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Protocol # 000860 Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
- Trial name
- NCT05588141
- Testing
- Zotiraciclib
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Oligodendroglioma, Oligodendroglioma, Anaplastic
PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
Proton therapy is a powerful tool enabling oncologists to spare normal tissue around the target for irradiation much better than what can be achieved with photon irradiation.
- Conditions
- Oligodendroglioma, Oligodendroglioma, Anaplastic, Diffuse Astrocytoma, IDH-Mutant
- Trial name
- PRO-GLIO (NCT05190172)
- Testing
- Radiation therapy
- Where
- Norway
- Volunteers
- 225 people
- Sponsor
- Oslo University Hospital
Glioma, IDH Mutation
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma.
- Conditions
- Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
- Trial name
- NCT05345002
- Testing
- Retifanlimab, All-trans retinoic acid
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Stephen Bagley, MD, MSCE
IDH Mutation, IDH1 Mutation
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
The purpose of this research is to gather information on the safety and effectiveness of fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib (two anti-cancer drugs).
- Conditions
- IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer
- Trial name
- NCT04955938
- Testing
- Ivosidenib, Enasidenib, Fedratinib
- Where
- United States
- Sponsor
- University of Chicago
Acute Myeloid Leukemia
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
This study is a multicenter, randomized, open-label, phase III clinical study (RAPHAEL) to evaluate the efficacy, safety, and PK of HMPL-306 versus salvage chemotherapy in patients with R/R AML harboring IDH1 and IDH2 mutations.
- Trial name
- NCT06387069
- Testing
- HMPL-306 Regimen, Salvage Chemotherapy Regimen
- Where
- 53 sites in China
- Volunteers
- 316 people
- Sponsor
- Hutchmed
Brain Glioma
Correlation Between SPECT/CT and IDH Mutation in Brain Glioma
Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas.Pentavalent 99mTc dimercaptosuccinic acid (99mTc (V)…
- Trial name
- NCT05595863
- Volunteers
- 40 people
- Sponsor
- Assiut University
Brain Tumor, Glioma
Metabolic Characterization of Space Occupying Lesions of the Brain
High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all…
- Conditions
- Brain Tumor, Glioma, IDH Mutation
- Trial name
- FASTMRSI (NCT04233788)
- Testing
- MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
- Where
- Switzerland
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Low-grade Glioma, IDH2 Gene Mutation
Niraparib In Recurrent IDH 1/2 Gliomas
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma.
- Conditions
- Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation
- Trial name
- NCT05406700
- Testing
- Niraparib, Resection/Treatment with Niraparib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, and best dose of a enasidenib in combination with cobimetinib in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment…
- Trial name
- NCT05441514
- Testing
- Cobimetinib, Enasidenib Mesylate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Oncology, Glioma
Monitoring of Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma
Patients with IDH-mutant glioma frequently experience symptoms such as fatigue, seizures, headaches, cognitive impairments (primarily attentional), and mood changes, which can significantly affect their health-related quality of…
- Trial name
- NEURO-PRO-GLIO (NCT07439302)
- Testing
- Neurocognitive assessment, Questionnaries QoL, Resilience Pro Application
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Residual or Recurrent Grade 2 IDH Mutant Glioma
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
The objective of this study is to determine the efficacy, safety, and pharmacokinetics of vorasidenib in Asian participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation.
- Trial name
- NCT06780930
- Testing
- Vorasidenib
- Where
- 8 sites in China, Taiwan
- Volunteers
- 57 people
- Sponsor
- Servier
Astrocytoma, Grade II, Astrocytoma, Grade III
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
Rationale: Standard postoperative treatment of isocitrate dehydrogenase 1/2 mutated grade 2 and 3 glioma (IDHmG) consists of radiotherapy and chemotherapy.
- Conditions
- Astrocytoma, Grade II, Astrocytoma, Grade III, Oligodendroglioma, Oligodendroglioma, Anaplastic
- Trial name
- RIGEL (NCT04304300)
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Glioma, Radiotherapy; Complications
Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Rationale: Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands.
- Trial name
- SOPRANO (NCT06180434)
- Testing
- proton therapy, photon therapy
- Where
- Netherlands
- Volunteers
- 320 people
- Sponsor
- Erasmus Medical Center